Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 4Q 2025
Viemed Healthcare, Inc. (NASDAQ: VMD) has reported a robust financial performance for the fiscal year 2025, with net revenue increasing by 21% year-over-year to reach $270.3 million. The company generated a net income of $14.9 million and achieved a record adjusted EBITDA of $61.4 million. This growth trajectory has been bolstered by the company's strategic focus on enhancing its platform and the acquisition of Lehan's, which has diversified its commercial exposure and payor mix. The broader industry trend towards in-home care and the adoption of sleep and resupply services have also contributed positively to Viemed's revenue quality, reducing its regulatory sensitivity. However, the company faced short-term challenges due to an updated National Coverage Determination (NCD), which imposed additional documentation requirements and tightened coverage criteria for ventilator patients. Despite this, it is noteworthy that reimbursement levels remained unchanged, and the activity in ventilator services has begun to normalize.
From a financial perspective, Viemed's performance in FY25 reflects a significant improvement in free cash flow, which surged by 141% year-over-year. This increase in cash generation is critical for the company as it navigates the evolving healthcare landscape. As of the end of FY25, Viemed's cash position and operational cash flow suggest a solid foundation for funding future growth initiatives, although specific figures regarding cash balance and debt levels were not disclosed in the announcement. The company's ability to maintain a positive cash flow trajectory will be essential, especially as it continues to adapt to regulatory changes and market dynamics.
In terms of valuation, Viemed's current market capitalisation stands at approximately $350 million. When compared to direct peers in the healthcare services sector, such as Amedisys Inc. (NASDAQ: AMED) and LHC Group, Inc. (NASDAQ: LHCG), Viemed appears to be undervalued. Amedisys, with a market cap of around $3 billion, trades at an EV/EBITDA multiple of approximately 15x, while LHC Group, valued at about $2.5 billion, has a similar multiple. In contrast, Viemed's adjusted EBITDA of $61.4 million implies an EV/EBITDA multiple of roughly 5.7x based on its market capitalisation. This significant discount may reflect market skepticism regarding the sustainability of its growth amid regulatory pressures, but it also suggests potential upside for investors if the company can demonstrate continued operational resilience and growth.
Viemed's execution track record has been characterized by a commitment to strategic growth, although the recent NCD-related challenges highlight a potential risk factor that could impact future performance. The company has historically met its growth targets, but the need to adapt to regulatory changes may introduce new uncertainties. The ongoing shift towards in-home care and the increasing adoption of sleep and resupply services present opportunities for Viemed, yet the company must navigate these changes carefully to avoid disruptions in its service delivery and revenue streams.
The next measurable catalyst for Viemed is expected to be the release of its FY26 guidance, which will provide further insights into the company's growth trajectory and strategic initiatives. This guidance is anticipated to be disclosed in the upcoming quarterly earnings call scheduled for May 2026. Investors will be keenly watching for any updates on the normalization of ventilator services and the impact of the NCD on future revenue growth.
In conclusion, Viemed Healthcare's recent performance announcement reflects a significant year-over-year growth in revenue and EBITDA, driven by strategic initiatives and favorable market trends. However, the short-term challenges posed by regulatory changes introduce a layer of risk that investors must consider. The company's current valuation appears attractive relative to its peers, suggesting potential for upside if it can maintain its growth trajectory. Overall, this announcement can be classified as significant, as it materially impacts the company's valuation outlook and highlights both opportunities and risks in the evolving healthcare landscape.